{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:24:06Z","timestamp":1795112646862,"version":"4.10.3"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To review recent advances in our understanding of the epidemiology, pathophysiology, and management of inclusion body myositis (IBM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent epidemiologic studies have highlighted the morbidity and mortality associated with IBM, including the impact of dysphagia. Multiomic analyses of IBM tissues have identified new pathogenic pathways and biomarkers for use in clinical trials. New diagnostic criteria and outcome measures have been proposed to improve clinical trial design. Ongoing clinical trials are targeting T cells and autophagy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Improvements in our understanding of IBM pathogenesis are identifying new pathways and biomarkers that need validation in larger cohorts. Exercise remains the primary therapeutic modality available, and new treatment targets are needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001060","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T10:00:10Z","timestamp":1730196010000},"page":"80-85","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Inclusion body myositis: an update"],"prefix":"10.1097","volume":"37","author":[{"given":"Nicolaas C.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ana.26412","article-title":"Epidemiology, survival, and clinical characteristics of inclusion body myositis","volume":"92","author":"Lindgren","year":"2022","journal-title":"Ann Neurol"},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"e2653","DOI":"10.1212\/WNL.0000000000012004","article-title":"Epidemiology and natural history of inclusion body myositis","volume":"96","author":"Shelly","year":"2021","journal-title":"Neurology"},{"key":"R3-20250108","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1007\/s00415-023-11878-w","article-title":"Inclusion body myositis with early onset: a population-based study","volume":"270","author":"Lindgren","year":"2023","journal-title":"J Neurol"},{"key":"R4-20250108","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1093\/rheumatology\/keab716","article-title":"Survival and associated comorbidities in inclusion body myositis","volume":"61","author":"Naddaf","year":"2021","journal-title":"Rheumatology"},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s13023-023-02902-3","article-title":"Cost of illness in inclusion body myositis: results from a cross-sectional study in Germany","volume":"18","author":"Senn","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"R6-20250108","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.3390\/jcm12155051","article-title":"Patient-reported health-related quality of life, anxiety and depression in patients with inclusion body myositis: a register-based cross-sectional study in Germany","volume":"12","author":"Senn","year":"2023","journal-title":"J Clin Med"},{"key":"R7-20250108","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12955-023-02196-w","article-title":"Inclusion body myositis\u2014health-related quality of life and care situation during phases of the \u2018patience journey\u2019 in Germany: results from a qualitative study","volume":"21","author":"Senn","year":"2023","journal-title":"Health Qual Life Outcomes"},{"key":"R8-20250108","first-page":"427","article-title":"Characterizing ventilatory muscle dysfunction in inclusion body myositis","volume":"102","author":"Brokamp","year":"2023","journal-title":"Am J Phys Med Rehabil"},{"key":"R9-20250108","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1212\/WNL.0000000000206777","article-title":"Clinical subgroups and factors associated with progression in patients with inclusion body myositis","volume":"100","author":"Michelle","year":"2023","journal-title":"Neurology"},{"key":"R10-20250108","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mus.27841","article-title":"Myositis-related autoantibody profile and clinical characteristics stratified by anticytosolic 5\u2032-nucleotidase 1A status in connective tissue diseases","volume":"68","author":"Diederichsen","year":"2023","journal-title":"Muscle Nerve"},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/mus.27157","article-title":"AnticN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis","volume":"63","author":"Paul","year":"2021","journal-title":"Muscle Nerve"},{"key":"R12-20250108","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/CND.0000000000000353","article-title":"Diagnostic accuracy of anti-CN1A on the diagnosis of inclusion body myositis. a hierarchical bivariate and Bayesian meta-analysis","volume":"23","author":"Mavroudis","year":"2021","journal-title":"J Clin Neuromusc Dis"},{"key":"R13-20250108","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nmd.2024.03.001","article-title":"272nd ENMC international workshop: 10 years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16\u201318 June 2023, Hoofddorp, The Netherlands","volume":"37","author":"Lilleker","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"R14-20250108","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00415-023-11986-7","article-title":"Face to face: deciphering facial involvement in inclusion body myositis","volume":"271","author":"Fortanier","year":"2024","journal-title":"J Neurol"},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.nmd.2022.11.008","article-title":"Clinical characteristics of dysphagic inclusion body myositis","volume":"33","author":"Taira","year":"2023","journal-title":"Neuromusc Disord"},{"key":"R16-20250108","first-page":"261","article-title":"In-patient comorbidities in inclusion body myositis: a United States national in-patient sample-based study","volume":"41","author":"Ma","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R17-20250108","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1093\/rheumatology\/keab754","article-title":"Inclusion body myositis: correlation of clinical outcomes with histopathology, electromyography and laboratory findings","volume":"61","author":"Pinto","year":"2021","journal-title":"Rheumatology"},{"key":"R18-20250108","doi-asserted-by":"crossref","first-page":"103150","DOI":"10.1016\/j.jaut.2023.103150","article-title":"High-resolution HLA genotyping in inclusion body myositis refines 8.1 ancestral haplotype association to DRB1\u221703:01:01 and highlights pathogenic role of arginine-74 of DR\u03b21 chain","volume":"142","author":"Slater","year":"2024","journal-title":"J Autoimmun"},{"key":"R19-20250108","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1093\/brain\/awz207","article-title":"Highly differentiated cytotoxic T cells in inclusion body myositis","volume":"142","author":"Greenberg","year":"2019","journal-title":"Brain"},{"key":"R20-20250108","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/jnen\/nlac067","article-title":"Immunohistochemical phenotype of T cells invading muscle in inclusion body myositis","volume":"81","author":"Matsubara","year":"2022","journal-title":"J Neuropathol Exp Neurol"},{"key":"R21-20250108","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/brain\/aww024","article-title":"Association of inclusion body myositis with T cell large granular lymphocytic leukaemia","volume":"139","author":"Greenberg","year":"2016","journal-title":"Brain"},{"key":"R22-20250108","doi-asserted-by":"crossref","first-page":"1153789","DOI":"10.3389\/fimmu.2023.1153789","article-title":"Uncovering the significance of expanded CD8+ large granular lymphocytes in inclusion body myositis: Insights into T cell phenotype and functional alterations, and disease severity","volume":"14","author":"McLeish","year":"2023","journal-title":"Front Immunol"},{"key":"R23-20250108","doi-asserted-by":"crossref","first-page":"e1504","DOI":"10.1002\/cti2.1504","article-title":"Identification of distinct immune signatures in inclusion body myositis by peripheral blood immunophenotyping using machine learning models","volume":"13","author":"McLeish","year":"2024","journal-title":"Clin Transl Immunol"},{"key":"R24-20250108","doi-asserted-by":"crossref","first-page":"e1374","DOI":"10.1212\/WNL.0000000000200013","article-title":"Immunophenotyping of inclusion body myositis blood T and NK cells","volume":"98","author":"Goyal","year":"2022","journal-title":"Neurology"},{"key":"R25-20250108","doi-asserted-by":"crossref","first-page":"eabi9196","DOI":"10.1126\/scitranslmed.abi9196","article-title":"Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis","volume":"14","author":"Britson","year":"2022","journal-title":"Sci Transl Med"},{"key":"R26-20250108","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adp5730","article-title":"Seeding competent TDP-43 persists in human patient and mouse muscle","author":"Lynch","year":"2024","journal-title":"Sci Transl Med"},{"key":"R27-20250108","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s43587-024-00645-9","article-title":"Cell type mapping of inflammatory muscle diseases highlights selective myofiber vulnerability in inclusion body myositis","volume":"4","author":"Wischnewski","year":"2024","journal-title":"Nat Aging"},{"key":"R28-20250108","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00296-024-05567-8","article-title":"Effects of sporadic inclusion body myositis on skeletal muscle fibre type specific morphology and markers of regeneration and inflammation","volume":"44","author":"Jensen","year":"2024","journal-title":"Rheumatol Int"},{"key":"R29-20250108","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00401-023-02637-2","article-title":"Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis","volume":"146","author":"Nelke","year":"2023","journal-title":"Acta Neuropathol"},{"key":"R30-20250108","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1007\/s00415-022-11029-7","article-title":"Comprehensive transcriptomic analysis shows disturbed calcium homeostasis and deregulation of T lymphocyte apoptosis in inclusion body myositis","volume":"269","author":"Johari","year":"2022","journal-title":"J Neurol"},{"key":"R31-20250108","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ana.26304","article-title":"Muscle transcriptomics shows overexpression of cadherin 1 in inclusion body myositis","volume":"91","author":"Ikenaga","year":"2022","journal-title":"Ann Neurol"},{"key":"R32-20250108","doi-asserted-by":"crossref","first-page":"11139","DOI":"10.3390\/ijms241311139","article-title":"Serum-circulating microRNAs in sporadic inclusion body myositis","volume":"24","author":"Lucchini","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R33-20250108","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jcsm.13178","article-title":"Unravelling inclusion body myositis using a patient-derived fibroblast model","volume":"14","author":"Cant\u00f3-Santos","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R34-20250108","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/acn3.51657","article-title":"Metabolome and transcriptome analysis on muscle of sporadic inclusion body myositis","volume":"9","author":"Murakami","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"R35-20250108","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3390\/antiox12081639","article-title":"Integrated multi-omics analysis for inferring molecular players in inclusion body myositis","volume":"12","author":"Cant\u00f3-Santos","year":"2023","journal-title":"Antioxidants"},{"key":"R36-20250108","doi-asserted-by":"crossref","first-page":"e200168","DOI":"10.1212\/CPJ.0000000000200168","article-title":"Study to assess content validity and interrater and intrarater reliability of the inclusion body myositis functional rating scale","volume":"13","author":"Symonds","year":"2023","journal-title":"Neurol Clin Pract"},{"key":"R37-20250108","doi-asserted-by":"crossref","first-page":"120228","DOI":"10.1016\/j.jns.2022.120228","article-title":"Reliability of patient self-reports to clinician-assigned functional scores of inclusion body myositis","volume":"436","author":"Roy","year":"2022","journal-title":"J Neurol Sci"},{"key":"R38-20250108","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2023.06.009","article-title":"Exploring hand and upper limb function in patients with inclusion body myositis (IBM)","volume":"33","author":"Hunn","year":"2023","journal-title":"Neuromusc Disord"},{"key":"R39-20250108","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.nmd.2022.08.005","article-title":"Correlations of disease severity outcome measures in inclusion body myositis","volume":"32","author":"Goyal","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"R40-20250108","doi-asserted-by":"crossref","first-page":"e865","DOI":"10.1212\/WNL.0000000000200776","article-title":"Longitudinal changes in MRI muscle morphometry and composition in people with inclusion body myositis","volume":"99","author":"Laurent","year":"2022","journal-title":"Neurology"},{"key":"R41-20250108","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/jcsm.13451","article-title":"Effect of sirolimus on muscle in inclusion body myositis observed with magnetic resonance imaging and spectroscopy","volume":"15","author":"Reyngoudt","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R42-20250108","doi-asserted-by":"crossref","first-page":"e1158","DOI":"10.1212\/WNL.0000000000207596","article-title":"Imaging with PET\/CT of diffuse CD8 T-cell infiltration of skeletal muscle in patients with inclusion body myositis","volume":"101","author":"Quinn","year":"2023","journal-title":"Neurology"},{"key":"R43-20250108","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/CND.0000000000000463","article-title":"Relationship between hand function and handheld ultrasound imaging in inclusion body myositis","volume":"25","author":"Black","year":"2024","journal-title":"J Clin Neuromuscul Dis"},{"key":"R44-20250108","first-page":"351","article-title":"A longitudinal study using B mode ultrasound and power Doppler as monitoring imaging tools in inclusion body myositis","volume":"42","author":"Paramalingam","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"R45-20250108","doi-asserted-by":"crossref","first-page":"jrm00386","DOI":"10.2340\/jrm.v55.5289","article-title":"Increasing daily duration of rehabilitation for inpatients with sporadic inclusion body myositis may contribute to improvement in activities of daily living: a nationwide database cohort study","volume":"55","author":"Tani","year":"2023","journal-title":"J Rehabil Med"},{"key":"R46-20250108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.nmd.2024.02.002","article-title":"Does inspiratory muscle training improve lung function and quality of life in people with inclusion body myositis? A pilot study","volume":"37","author":"Williams","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"R47-20250108","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CND.0b013e3181a23c86","article-title":"Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis","volume":"10","author":"Johnson","year":"2009","journal-title":"J Clin Neuromuscul Dis"},{"key":"R48-20250108","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1097\/RHU.0000000000001997","article-title":"Palliative care utilization for hospitalized patients with inclusion body myositis: a nationwide study","volume":"29","author":"Kuchinad","year":"2023","journal-title":"J Clin Rheumatol"},{"key":"R49-20250108","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S1474-4422(23)00275-2","article-title":"Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Machado","year":"2023","journal-title":"Lancet Neurol"},{"key":"R50-20250108","doi-asserted-by":"crossref","first-page":"e1595","DOI":"10.1212\/WNL.0000000000011626","article-title":"Efficacy and safety of bimagrumab in sporadic inclusion body myositis","volume":"96","author":"Amato","year":"2021","journal-title":"Neurology"},{"key":"R51-20250108","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R52-20250108","doi-asserted-by":"crossref","first-page":"e0283394","DOI":"10.1371\/journal.pone.0283394","article-title":"Testosterone treatment combined with exercise to improve muscle strength, physical function and quality of life in men affected by inclusion body myositis: a randomised, double-blind, placebo-controlled, crossover trial","volume":"18","author":"Connor","year":"2023","journal-title":"PLoS One"},{"key":"R53-20250108","doi-asserted-by":"crossref","first-page":"e1416","DOI":"10.1002\/cti2.1416","article-title":"Immunoregulatory effects of testosterone supplementation combined with exercise training in men with inclusion body myositis: a double-blind, placebo-controlled, cross-over trial","volume":"11","author":"Coudert","year":"2022","journal-title":"Clin Transl Immunol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:07:43Z","timestamp":1736334463000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001060","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]}}}